Edgar R. Wood

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Edgar R. Wood, Anne T. Truesdale, Octerloney B. McDonald et al. · Cancer Research · 2004 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +14

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

David W. Rusnak, Karen Lackey, Karen Affleck et al. · PubMed · 2001 · 738 citations

Medicine, Oncology, Pharmacology +17

The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine.

J. Brice Weinberg, Donald L. Granger, David S. Pisetsky et al. · The Journal of Experimental Medicine · 1994 · 440 citations · Full text

Medicine, Immunology, Pathology +17

Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Nelson Rhodes, Dirk A. Heerding, Derek R. Duckett et al. · Cancer Research · 2008 · 298 citations · Full text

Medicine, Oncology, Pharmacology +17

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

David W. Rusnak, Karen Affleck, Stuart Cockerill et al. · PubMed · 2001 · 297 citations

Medicine, Oncology, Pharmacology +15